Cloud Banner

Healthcare

Image

Global Heart Failure Drugs Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Heart Failure Drugs Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - 15.56% Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 8010.62 Million
Diagram Market Size (Forecast Year) USD 24919.55 Million
Diagram CAGR 15.56%

Global Heart Failure Drugs Market, By Type (ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blocker, Diuretics, Others), Application (Injection, Capsule, Tablets), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Specialty Centres, Others) - Industry Trends and Forecast to 2030.

 Heart Failure Drugs Market

Heart Failure Drugs Market Analysis and Size

The increase in the rate of cardiovascular cases among people and the growing geriatric population globally are the major factors driving the heart failure drugs market. The increase in the need for these drugs as they treat different symptoms of the disorder and the patient's dependency on them accelerates the growth of heart failure drugs. The change in lifestyle, such as excessive alcohol consumption, smoking, and unhealthy diet habits, causes heart problems propelling the heart failure drugs market. The increase in investment by key players and the increase in research and development activities influence the heart failure drugs market. Additionally, increased heart problems due to obesity and lack of physical activities boost the heart failure drugs market. Furthermore, the rise in demand for effective drugs and treatment and product approval extends profitable opportunities to the market of heart failure drugs.

However, the side effects of consuming these drugs are expected to obstruct the heart failure drug market growth. Rising concerns regarding increasing contractility may damage the myocardium and shorten the survival of these patients is projected to challenge the heart failure drugs market.     

Data Bridge Market Research analyses that the heart failure drugs market which was USD 8,010.62 million in 2023, would rocket up to USD 24,919.55 million by 2030, and is expected to undergo a CAGR of 15.56% during the forecast period. This indicates that the market value. "Beta blockers" dominates the type segment of the heart failure drugs market due to increasing awareness about heart failure drugs. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Heart Failure Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Type (ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, Others), Application (Injection, Capsule, Tablets), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Specialty Centres, Others)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa

Market Players Covered

Amgen Inc. (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Gilead Sciences, Inc (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Cardurion Pharmaceuticals (U.S.), Cardior Pharmaceuticals (Germany), Actelion Pharmaceuticals Ltd (Switzerland), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (U.S.), CYTOKINETICS, INC. (U.S.), and Eli Lilly and Company (U.S.) among others.

Market Opportunities

  • Rising demand for minimally invasive treatments
  • Development of new formulations and delivery methods
  • Rising personalized medicine approaches

Market Definition

The heart failure drugs market refers to the global pharmaceutical industry segment that encompasses developing, producing, and commercializing medications specifically designed to treat heart failure. Heart failure is a chronic medical condition characterized by the heart's inability to pump enough blood to meet the body's demands. This market focuses on drugs that aim to alleviate symptoms, improve heart function, and enhance patients' quality of life.

Heart failure drugs include a range of therapeutic agents targeting different aspects of the condition, such as reducing fluid build-up, managing blood pressure, improving cardiac contractility, and addressing underlying causes. These medications can include diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, aldosterone antagonists, and others.

Heart Failure Drugs Market Dynamics

Drivers

  • Increasing Prevalence of Heart Failure

The global prevalence of heart failure is rising due to an aging population, sedentary lifestyles, unhealthy dietary habits, and increased risk factors like obesity, diabetes, and hypertension. This growing patient population fuels the demand for effective heart failure drugs.

  • Rising Awareness and Early Diagnosis

Increasing awareness about heart failure symptoms, risk factors, and the importance of early diagnosis has resulted in more patients seeking medical help at an earlier stage. Timely diagnosis enables prompt initiation of treatment, leading to a greater demand for heart failure drugs.

  • Growing Healthcare Expenditure

Rising healthcare expenditure globally, especially in developed economies, increases access to healthcare services and medications. Governments and private insurers often cover a significant portion of the costs associated with heart failure drugs, making them more accessible to patients.  

Opportunities

  • Technological Advancements and Medical Innovations

Medical research and technological advances have led to development of novel therapeutic approaches and drug formulations for heart failure treatment. These innovations include introducing new drug classes, improved drug delivery systems, and targeted therapies, enhancing the effectiveness and safety of heart failure drugs.

Restraint/Challenge

  • High Development Costs

The research, development, and clinical trial costs of bringing a heart failure drug to market can be substantial. The extensive investment required and the risk of failure during the development process can deter some pharmaceutical companies from pursuing research in this field. High development costs may limit the number of new drugs entering the market and potentially slow innovation.

This heart failure drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Heart failure drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In September 2022, Bayer launched a novel heart failure drug in India that it has co-developed with Merck at one-fifteenth of the global price at Rs 127 per pill. It's a one-pill-a-day therapy. Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalization among worsening heart failure patients.

Global Heart Failure Drugs Market Scope

The heart failure drugs market is segmented on the basis of type, application, distribution channel, and end users. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.

Type

  • ACE Inhibitors
  • Angiotensin Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Others

Application

  • Injection
  • Capsule
  • Tablets
  •  

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users

  • Hospitals
  • Specialty Centres
  • Others

Heart failure drugs Market Regional Analysis/Insights

The Heart failure drugs market is analysed and market size insights and trends are provided by country, type, application, distribution channel, and end usesr as referenced above.

The countries covered in the Heart failure drugs market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa.

North America is expected to dominate the global heart failure drugs market due to the increasing prevalence of heart disease in that region.

Asia-Pacific is the fastest-growing region due to increasing awareness and interest in health and wellness.

The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The heart failure drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for heart failure drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2015-2020.

Competitive Landscape and Heart Failure Drugs Market Share Analysis

The heart failure drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the heart failure drugs market are:

  • Amgen Inc. (U.S.)
  • AstraZeneca (U.K.)
  • Bayer AG (Germany)
  • Novartis AG (Switzerland)
  • Gilead Sciences, Inc (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Pfizer Inc. (U.S.)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Cardurion Pharmaceuticals (U.S.)
  • Cardior Pharmaceuticals (Germany)
  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Boehringer Ingelheim International GmbH (Germany)
  • Bristol-Myers Squibb Company (U.S.)
  • CYTOKINETICS, INC. (U.S.)
  • Eli Lilly and Company (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Heart Failure Drugs Market will be worth USD 24,919.55 million by 2030.
The Heart Failure Drugs Market Growth Rate is 15.56% during the forecast period.
Growing Healthcare Expenditure, Rising Awareness, and Early Diagnosis and Increasing Prevalence of Heart Failure are the Growth drivers of the Heart Failure Drugs Market.
The type, application, distribution channel, and end users are the factors on which the Heart Failure Drugs Market research is based.
Bayer launched a novel heart failure drug in India that it has co-developed with Merck at one-fifteenth of the global price at Rs 127 per pill. It's a one-pill-a-day therapy. Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalization among worsening heart failure patients are the latest developments in the Heart Failure Drugs Market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials